Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After...

愛德華生命科學表示，EARLY TAVR試驗顯示，在最初的6個月內，臨床監測組中有26.2％的患者轉爲AVR，許多患者出現進行性或先進症狀；在隨機分組後的12個月後隨訪期間...

Benzinga · 10/28 23:15

Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After Randomization, The Rate Of Conversion To AVR Was 47.2%

愛德華生命科學表示，EARLY TAVR試驗顯示，在最初的6個月內，臨床監測組中有26.2％的患者轉爲AVR，許多患者出現進行性或先進症狀；在隨機分組後的12個月隨訪期後，轉爲AVR的比例爲47.2％

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。